

AZD8330

Catalog No: tcsc0217



Available Sizes

Size: 5mg

Size: 10mg

Size: 50mg

Size: 100mg



Specifications

CAS No:

869357-68-6

Formula:

$C_{16}H_{17}FIN_3O_4$

Pathway:

MAPK/ERK Pathway

Target:

MEK

Purity / Grade:

>98%

Solubility:

10 mM in DMSO

Alternative Names:

ARRY-424704;ARRY-704

Observed Molecular Weight:

461.23


Product Description

AZD8330 (ARRY-424704) is a potent, uncompetitive **MEK1/MEK2** inhibitor, with an **IC₅₀** of 7 nM.

IC50 & Target: IC50: 7 nM (MEK1/MEK2)^[1]

In Vitro: AZD8330 is a selective allosteric MEK1/ MEK2 inhibitor. Exposing human osteosarcoma cell lines MOS, U2OS, and 143B to a concentration of 0.5 µM of Trametinib, AZD8330 or TAK-733 for 6 hours, leads to loss of ERK phosphorylation indicating effective MEK inhibition. The activity of these three inhibitors is tested using concentration ranges in six osteosarcoma cell lines: MOS, U2OS, KPD, ZK58, 143b and Saos-2. All three inhibitors decrease viability of MOS and U2OS and strongly affect 143b. By contrast, viability of KPD, ZK58 and Saos-2 is not affected by any of the three inhibitors^[2].

In Vivo: In tumour xenograft models, AZD8330 demonstrates dose-dependent tumour growth inhibition of approximately 90% at tolerated doses (1.0 mg/kg once daily [OD])^[1].



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!